Canada's largest listed drug maker, Valeant Pharmaceuticals International Inc, is in talks to buy generic drugmaker Actavis Inc for more than $13 billion, a person familiar with the situation told Reuters on Friday night.
Drug maker Valeant in talks on $13 billion Actavis buy: source
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.